Novavax Appoints Mark Twyman Vice President Marketing
GAITHERSBURG, Md., 2015-12-21 22:05 CET (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced the appointment of Mark Twyman to the position of Vice President, Marketing. Mr. Twyman’s efforts will be focused on the commercial launch of the company’s RSV F Vaccine.
Mr. Twyman joins Novavax with more than 20 years of experience commercializing healthcare products including key roles at Merck, MedImmune and Genzyme.His eighteen year tenure at Merck included 12 years in the Merck Vaccine Division, where he held roles of increasing responsibility, including Vice President, Global Marketing for the pediatric vaccine franchise.At MedImmune he served as Vice President and General Manager for the influenza program. Mr. Twyman earned an M.B.A. fromThe Wharton Schoolof theUniversity of Pennsylvaniaand a Bachelor of Arts degree fromDickinson College.
“We are delighted to welcome Mark to our team,” said John Trizzino, Senior Vice President, Commercial Operations. “His depth of experience in vaccine marketing and commercialization efforts will be an important asset as Novavax prepares to bring its RSV F Vaccine franchise to market.”
Novavax, Inc.(Nasdaq:NVAX) is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Our recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. Additional information aboutNovavaxis available on the company’s website,novavax.com.
Information om Nasdaq OMX
Følg pressemeddelelser fra Nasdaq OMX
Skrive dig op her og du vil løbende modtage pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Nasdaq OMX
Aptean17.1.2018 21:01 | pressemeddelelse
Partnership With FAST Technologies Expands Aptean's European Footprint
World Finance17.1.2018 15:30 | pressemeddelelse
Egyptian Steel recognised in the World Finance 100 guide for 2017
European CEO17.1.2018 15:07 | pressemeddelelse
Investing in Berlin's thriving real estate market
Crown Bioscience Inc.17.1.2018 14:14 | pressemeddelelse
Innovative Humanized Research Strategies for Immuno-Oncology Drug Development, Crown Bioscience Hosts a Live Webinar
Colliers International Group Inc.17.1.2018 13:33 | pressemeddelelse
Colliers Launches Real Estate Technology Accelerator With Techstars
BnkToTheFuture17.1.2018 13:17 | pressemeddelelse
BnkToTheFuture Raises Initial $30 Million for Tokenized Securities Market and Due Diligence Platform
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum